Overview

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2032-10-31

Target enrollment:

Participant gender:

Summary

The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Treatments:

osimertinib